Recently, a study sought to determine whether dose reductions of anti–tumor necrosis factor (anti-TNF) therapies are possible for long-term treatment of spondyloarthritis, and found that a reduced dose is noninferior to a full dose in patients in sustained clinical remission.
Anti—tumor necrosis factor (anti-TNF) therapies are often efficacious in treating spondyloarthritis, but the optimal duration and dose for long-term treatment are not yet clear; currently, doses recommended for acute and chronic disease are the same. In addition to the high cost of these drugs and their potential to increase the risk of serious infections, it is not yet known whether chronic use may increase malignancies or demyelinating diseases. Recently, a study sought to determine whether dose reductions are possible for long-term treatment of spondyloarthritis, and found that a reduced dose is noninferior to a full dose in patients in sustained clinical remission.
The prospective, multicenter, randomized open-label trial was conducted at 22 studies in Spain. Patients were eligible to enroll if they were taking the recommended dose of infliximab, adalimumab, etanercept, or golimumab and had been in clinical remission for 6 months or more.
The 126 enrolled patients were randomized to receive either the full recommended dose of their anti-TNF agent (n = 63) or a reduced dose (n = 63), according to an agreed-upon protocol. For example, in those taking adalimumab, patients with standard dosing received 40 mg every 2 weeks, while the reduced dose group received 40 mg every 3 weeks. In those taking infliximab, the full-dose group received 5 mg per kg every 6 to 8 weeks, while the reduced-dose group received 3 mg per kg every 8 weeks. The primary end point was the proportion of patients with low disease activity (LDA) at 1 year.
The study found that the proportion of patients with LDA at 1 year was 83.9% (95% CI, 64.8%-102.7%) in the full-dose arm and 81.3% (95% CI, 62.8%-99.8%) in the reduced-dose arm. The absolute difference in LDA at 1 year in the per-protocol set population was —2.5% (95% CI, –16.6 to 11.7%). The lower bound for the CI in the control arm was greater than 60%, fulfilling prespecified validation criteria.
The percentage of patients in clinical remission, a key secondary end point, at 1 year was 83.7% (95% CI, 64.7%-102.7%) in the full-dose arm and 78.2% (95% CI, 59.7%-96.8%) in the reduced-dose arm, with absolute differences between treatment groups of −5.5% (95% CI, −20.6% to 9.7%) (P = .480)
Serious treatment-related adverse events or infections were reported in 11.3% of the full-dose group, and in 3.3% of the reduced-dose group (P = .164). Treatment was discontinued by 9.7% of the full-dose group and 21.3% of the reduced-dose group (P = .086).
“This trial has shown that a dose-reduction strategy may be non-inferior to full-dose treatment in patients with AS in persistent clinical remission with [anti-TNF agents], in terms of maintenance of LDA after 1 year,” write the investigators.
Reference
Gratacós J, Pontes C, Juanola X, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondylarthrosis. Arthritis Res Ther. 2019;21(1):11. doi: 10.1186/s13075-018-1772-z.
Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis
December 3rd 2024The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.